Drug intelligence / Profile preview

BNT165e

Development stage: Unknown
Lead developer: BioNTech
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

**BNT165e** is BioNTech's investigational multi-antigen, lipid nanoparticle-formulated mRNA vaccine for prevention of *Plasmodium falciparum* malaria. The product contains three distinct RNA components: BNT165c, which encodes the full *P. falciparum* circumsporozoite protein, and BNT165d1 plus BNT165d2, which encode conserved immunogenic segments of liver-stage-expressed *P. falciparum* proteins. Vaccination is intended to induce protective immune responses against parasite antigens expressed during the pre-erythrocytic liver stage. BNT165e was evaluated in the randomized Phase I/IIa BNT165-02 trial in healthy malaria-naive adults.

Targets

pMHC–TCR (Peptide–MHC–T-cell receptor complex)

Beyond the preview

Go deeper on BNT165e.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNT165e.

Explore the full profile